Zydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon USFDA approval.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2L15hJm
via IFTTT
0 comments:
Post a Comment